Sygnis

Sygnis in Medical Technology

Sygnis Pharma AG announces date for presentation of clinical results

...IDELBERG, Germany, 11 July 2007 – On 23 July sygnis Pharma AG will present the results of the clinical...ke place on 28 November 2007 in Eppelheim. About sygnis Pharma sygnis Pharma AG, with head offices in Heidelberg, is a s...

Sygnis in Biological News

TGen and ASU researchers find drug that could reduce risk of Alzheimer's

...y have no competing financial interests. Four of the authors hold stock in sygnis Pharma AG, a German pharmaceutical company that owns the rights to develop this drug class as a potential memory enhancer. They stated that sygnis was not directly involved in this study, did not fund any part of it, and d...

Brain protein improves stroke symptoms in rats, even when injected after 3 days

...humans. The BMC Biology study is the first to show that G-CSF can be effective when injected this late after a stroke event. Armin Schneider from sygnis Bioscience AG (formerly known as Axaron Bioscience AG) in Heidelberg, Germany, and Wolf-Rüdiger Schäbitz from the Neurology department in Münster, Ger...

Sygnis in other areas

SYGNIS Pharma AG - The Company

SYGNIS Pharma AG, Heidelberg, is a specialist pharmaceutical company listed on ... In doing so, SYGNIS takes a dual therapeutic approach that aims to effect both ...

SYGNIS Pharma AG - Amnestix Inc.

... with its own CNS-expertise SYGNIS is securing the future input of ... In addition SYGNIS gains direct access to the leading neurogenomic expertise of TGen. ...

LIO - SYGNIS Pharma AG - Google Finance

Get the latest on SYGNIS Pharma AG (LIO) including up to date news, high quality discussion groups and more on Google Finance.

=> EANS-News: SYGNIS treibt die Entwicklung von AX200 im ersten Quartal ...

SYGNIS advances development of AX200 in Q1 2009/2010, : SYGNIS Pharma AG published its financial results for the first quarter of the fiscal year 2009/2010, which ...

SYGNIS Pharma buy, 10.08.2009 - Nachrichten / News von finanztreff.de

News and press releases from the pharmaceutical industry. ... In the past year SYGNIS has made significant progress in the development of ...

SYGNIS advances development of AX200 in Q1 2009/2010 - News Press ...

News and press releases from the pharmaceutical industry. ... as well as obtaining necessary regulatory approvals, SYGNIS initiated a phase II efficacy ...

Other TagsFreer Halle Halle Halle Halle Elevator

Hajek McCollough Roger Haberman Pennington Woodson Freer Gorney Halle Henner Lempert Elevator Tenzel Delicate

(Date:12/5/2009)... and myeloproliferative disorders are serious and often deadly ... Annual Meeting of the American Society of Hematology ... methods for patients suffering from acute promyelocytic leukemia, ... myelofibrosis that are based on a better understanding ...

(Date:12/5/2009)... innovative new international private medical insurance plan which follows the acclaimed ... the flexibility to add or remove a wide range of options ... tailor their benefits to complement those already offered in their country ... ...

(Date:12/4/2009)... Investment Trust Inc. (NYSE: CRE ) ("Care" or ... a dividend of $0.17 per share of common stock. The ... record on December 14, 2009. ,, About ... real estate investment and finance company investing in healthcare-related real estate ...

(Date:12/4/2009)... Association of Homes and Services for the Aging (AAHSA) applauds ... Supportive Services (CLASS) provisions remain in the final health reform ... to elders, people with disabilities and their caregivers. ,, ... bill that will make it affordable to care for families ...

(Date:12/4/2009)... Bowen, Chief Information Officer at Crescent Healthcare, was selected ... Award for transforming Crescent,s business with the power of ... their innovative usage of Salesforce CRM or the Force.com ... their sales, marketing, partner, service, support or IT organizations. ...

[0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders [0] AVIVA's Private Health Insurance Products Solutions Go International [0] Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share [0] Statement from AAHSA CEO Larry Minnix on the Failure of the Thune Amendment [0] Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist

(Date:12/3/2009)... a social snubbing? Your genetics, not your friends, may be ... called opioids, relieve not only physical pain, but also some ... Faculty of 1000 Biology member Markus Heilig shows that small ... determine the intensity of people,s responses to social rejection. ...

(Date:12/3/2009)... NY A team of scientists from the U.S. ... and the Indian Institute of Science has made a ... information in DNA that is necessary to carry out ... 1, 2009 edition of Nature Structural & Molecular ...

(Date:12/2/2009)... evidence that people who smoke cigarettes over a long ... colorectal cancer, even after adjusting for other risk factors. ... smoke, or to quit as soon as possible," said ... emeritus, epidemiology and surveillance research at the American Cancer ...

Breaking Biology News(10 mins):Grooving down the helix 2 Grooving down the helix 3 Cigarette smoking increases colorectal cancer risk 2 HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 1 HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 2 HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 3 CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 1 CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 2 CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 3 CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 4 Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 1 Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 2 Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 3 Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 4

[0] Love hurts: Why emotional pain really affects us [0] Grooving down the helix [0] Cigarette smoking increases colorectal cancer risk

Other Contentsbronchiectasis bronchitis bronchitis bronchitis bronchoscopy bronchoscopy bronchiolitis bronchiolitis brucellosis bruises bruises bubonic bubonic bubonic

bronchiectasis bronchitis bronchoscopy bronchiolitis brucellosis bruises bubonic bronchopneumonia